Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats

被引:33
作者
Hazra, Anasuya [1 ,3 ]
Pyszczynski, Nancy A. [1 ]
DuBois, Debra C. [1 ,2 ]
Almon, Richard R. [1 ,2 ]
Jusko, William J. [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA
[3] Pfizer Inc, Dept Clin Pharmacol, New London, CT 06380 USA
关键词
cholesterol; corticosteroids; glucocorticoid receptors; LDL receptors; lipids; pharmacodynamics;
D O I
10.1007/s11095-007-9371-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. This study examines methylprednisolone (MPL) effects on the dynamics of hepatic low-density lipoprotein receptor (LDLR) mRNA and plasma lipids associated with increased risks for atherosclerosis. Materials and Methods. Normal male Wistar rats were given 50 mg/kg MPL intramuscularly (IM) and sacrificed at various times. Measurements included plasma MPL and CST, hepatic glucocorticoid receptor (GR) mRNA, cytosolic GR density and hepatic LDLR mRNA, and plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), and triglycerides (TG). Results. MPL showed bi-exponential disposition with two first-order absorption components. Hepatic GR and LDLR mRNA exhibited circadian patterns which were disrupted by MPL. Down-regulation in GR mRNA (40-50%) was followed by a delayed rebound phase. LDLR mRNA exhibited transient down-regulation (60-70%). Cytosolic GR density was significantly suppressed but returned to baseline by 72 h. Plasma TC and LDLC showed increases (55 and 142%) at 12 h. A mechanistic receptor/gene pharmacokinetic/pharmacodynamic model was developed to describe CS effects on hepatic LDLR mRNA and plasma cholesterols. Conclusions. Our PK/PD model was able to satisfactorily capture the MPL effects on hepatic LDLR, its relationship to various plasma cholesterols, and builds the foundation to explore this area in the future.
引用
收藏
页码:769 / 780
页数:12
相关论文
共 42 条
[1]   DEVELOPMENT OF HYPERCHOLESTEREMIA DURING CORTISONE AND ACTH THERAPY [J].
ADLERSBERG, D ;
SCHAEFER, L ;
DRACHMAN, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1950, 144 (11) :909-914
[2]   In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR) [J].
Almon, RR ;
Chen, J ;
Snyder, G ;
DuBois, DC ;
Jusko, WJ ;
Hoffman, EP .
PHARMACOGENOMICS, 2003, 4 (06) :791-799
[3]   Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells [J].
AlRayyes, O ;
Wallmark, A ;
Floren, CH .
HEPATOLOGY, 1997, 26 (04) :967-971
[4]   INFLUENCE OF ROUTE OF ADMINISTRATION ON THE PHARMACOKINETICS OF METHYLPREDNISOLONE [J].
ANTAL, EJ ;
WRIGHT, CE ;
GILLESPIE, WR ;
ALBERT, KS .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1983, 11 (06) :561-576
[5]   GLUCOCORTICOIDS AND TRIGLYCERIDE TRANSPORT - EFFECTS ON TRIGLYCERIDE SECRETION RATES, LIPOPROTEIN-LIPASE, AND PLASMA LIPOPROTEINS IN RAT [J].
BAGDADE, JD ;
YEE, E ;
ALBERS, J ;
PYKALISTO, OJ .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1976, 25 (05) :533-542
[6]   CIRCADIAN-RHYTHM IN HEPATIC LOW-DENSITY-LIPOPROTEIN (LDL)-RECEPTOR EXPRESSION AND PLASMA LDL LEVELS [J].
BALASUBRAMANIAM, S ;
SZANTO, A ;
ROACH, PD .
BIOCHEMICAL JOURNAL, 1994, 298 :39-43
[7]   High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions [J].
Barter, P ;
Kastelein, J ;
Nunn, A ;
Hobbs, R .
ATHEROSCLEROSIS, 2003, 168 (02) :195-211
[8]   DNA REGULATORY ELEMENTS FOR STEROID-HORMONES [J].
BEATO, M ;
CHALEPAKIS, G ;
SCHAUER, M ;
SLATER, EP .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 32 (05) :737-748
[9]   PREVALENCE OF HYPERLIPIDEMIA IN HEART-TRANSPLANT RECIPIENTS [J].
BECKER, DM ;
MARKAKIS, M ;
SENSION, M ;
VITALIS, S ;
BAUGHMAN, K ;
SWANK, R ;
KWITEROVICH, PO ;
PEARSON, TA ;
ACHUFF, SC ;
BAUMGARTNER, WA ;
BORKON, AM ;
REITZ, BA ;
TRAILL, TA .
TRANSPLANTATION, 1987, 44 (02) :323-325
[10]  
Bilheimer D W, 1984, Agents Actions Suppl, V16, P191